Cargando…

PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis

PURPOSE: PIK3CA mutation is considered to be a possible cause for resistance to neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the association between PIK3CA mutations and the outcome of NAC in HER2-positive breast cancers. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Youjeong, Park, Yeon Hee, Ahn, Jin Seok, Im, Young-Hyuck, Nam, Seok Jin, Cho, Soo Youn, Cho, Eun Yoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310726/ https://www.ncbi.nlm.nih.gov/pubmed/30607159 http://dx.doi.org/10.4048/jbc.2018.21.e48

Ejemplares similares

Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period
por: Choi, Misun, et al.
Publicado: (2017)

A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Hae Hyun, et al.
Publicado: (2023)

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
por: Jung, Hae Hyun, et al.
Publicado: (2021)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

The Prognostic Impact of Synchronous Ipsilateral Multiple Breast Cancer: Survival Outcomes according to the Eighth American Joint Committee on Cancer Staging and Molecular Subtype
por: Chu, Jinah, et al.
Publicado: (2018)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level
por: Ryu, Jai Min, et al.
Publicado: (2023)

Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay
por: Lee, Jun-Hee, et al.
Publicado: (2022)

Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
por: Kim, Joo Hoon, et al.
Publicado: (2016)

Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy
por: Jang, Yunjeong, et al.
Publicado: (2019)

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Radiation Treatment in Pathologic N0-N1 Patients Treated with Neoadjuvant Chemotherapy Followed by Surgery for Locally Advanced Breast Cancer
por: Bae, Sun Hyun, et al.
Publicado: (2012)

Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer
por: Park, Jieun, et al.
Publicado: (2023)

Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
por: Lee, Su Jin, et al.
Publicado: (2011)

The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
por: Park, Kyunghee, et al.
Publicado: (2015)

Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus
por: Miranda, Ludmilla Queirós, et al.
Publicado: (2013)

Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer
por: Cho, Dong Hui, et al.
Publicado: (2013)

Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma
por: Lee, Hong Kyu, et al.
Publicado: (2020)

Prognostic value of ERBB4 expression in patients with triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations
por: Moon, Jai-Hee, et al.
Publicado: (2019)

Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines
por: Yeom, Jiah, et al.
Publicado: (2023)

Prediction of PIK3CA mutations from cancer gene expression data
por: Kang, Jun, et al.
Publicado: (2020)

Permanent Chemotherapy‐Induced Alopecia in Patients with Breast Cancer: A 3‐Year Prospective Cohort Study
por: Kang, Danbee, et al.
Publicado: (2018)

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
por: Park, Hyung Kyu, et al.
Publicado: (2017)

Pik3ca is required for mouse uterine gland development and pregnancy
por: Chang, Hye Jin, et al.
Publicado: (2018)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?
por: Cho, Won Kyung, et al.
Publicado: (2018)

Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry
por: Kim, Ji-Yeon, et al.
Publicado: (2019)

PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer
por: Kim, Ji-Won, et al.
Publicado: (2017)

Segmental epidermal nevus and mucosal neuromas associated with PIK3CA-related overgrowth spectrum disorder
por: Roth, Gretchen M., et al.
Publicado: (2018)

Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer
por: Jang, Si-Hyong, et al.
Publicado: (2016)

Clinicopathological Characteristics of PIK3CA Mutation and Amplification in Korean Patients with Breast Cancers
por: Lee, Moo-Hyun, et al.
Publicado: (2020)

Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer
por: Park, Yoon Sun, et al.
Publicado: (2023)

Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
por: Ha, Joo Young, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9htprh5jasiq96ajmjr6vp0hp4